| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_156a3882c96c3803ba52ee50ded7f327 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 |
| filingDate |
2009-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3670829af974ab32ee296c13fd592b6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_505cd9be4e598ee53089ef7b359a70b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8726c930981d9daf9805441e623ef55b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ac3fae3fad73e142caa13f4efa3ee76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_befcc974a15510bb34dc90061790955a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8997e68da2ba828fbf9b96f4015f8167 |
| publicationDate |
2013-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013013327-A |
| titleOfInvention |
Antibody binding to MANSC1 protein and having anticancer activity |
| abstract |
[Problem] To provide a novel antibody having excellent anticancer activity and a drug for treating or diagnosing cancer comprising the antibody as an active ingredient, and using the SST-REX method. CDNAs encoding proteins expressed on the cell surface or secreted from the cells are selected from the cDNA library of, and monoclonal antibodies against the proteins encoded by the selected cDNAs are prepared to examine anticancer activity in vitro and in vivo As a result, a monoclonal antibody that binds to the MANSC1 protein and has an excellent anticancer activity was found. Furthermore, the region including the epitope of this antibody in the MANSC1 protein was identified, and the structure of the variable region of the light chain and heavy chain of this antibody was successfully determined. [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016175307-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2016175307-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11129893-B2 |
| priorityDate |
2009-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |